Clinicopathological features and epidermal growth factor receptor mutations associated with epithelial-mesenchymal transition in non-small cell lung cancer

Respirology

Volumn 14, Issue 3, 2009, Pages 371-376

  Deng, Qin Fang ^a   Zhou, Cai Cun ^a   Su, Chun Xia ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Epithelial mesenchymal transition; Lung cancer

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; UVOMORULIN; VIMENTIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CELL TRANSFORMATION; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MESENCHYME CELL; MUTATIONAL ANALYSIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; ENZYME INHIBITORS; EPITHELIAL CELLS; FEMALE; GENOTYPE; HUMANS; LOGISTIC MODELS; LUNG NEOPLASMS; MALE; MESODERM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; NEOPLASM STAGING; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; VIMENTIN;

EID: 63849273059     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2009.01496.x     Document Type: Article

References (26)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A et al. American Cancer Society. Cancer statistics 2004. CA Cancer J. Clin. 2004 54 : 8 29.
2. Breathnach OS, Freidlin B, Conley B, Green MR, Johnson DH et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J. Clin. Oncol. 2001 19 : 1734 42.
3. Shepherd FA, Pereira J, Ciuleanu TE, Tan EH, Hirsh V et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol. 2004 22 (Suppl.): 7022.
4. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J. Clin. Oncol. 2005 23 : 2556 68.
5. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003 15 : 740 6.
6. Grunert S, Jechlinger M, Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell. Biol. 2003 4 : 657 65.
7. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002 2 : 442 54.
8. Thomson S, Buck E, Petti F, Griffin G, Brown E et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005 65 : 9455 62.
9. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin. Cancer Res. 2005 11 : 8686 98.
10. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 304 : 1497 500.
11. Rusch V, Baselga J, Cordon-Cardo C, Orazem J, Zaman M et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 1993 53 : 2379 85.
12. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000 6 : 4885 92.
13. Baselga J. Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact? J. Clin. Oncol. 2004 22 : 759 61.
14. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A et al. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J. Clin. Oncol. 2002 20 : 2417 28.
15. Comoglio PM, Boccaccio C, Trusolino L. Interactions between growth factor receptors and adhesion molecules: breaking the rules. Curr. Opin. Cell Biol. 2003 15 : 565 71.
16. Deeb G, Wang J, Ramnath N, Slocum HK, Wiseman S et al. Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry. Mod. Pathol. 2004 17 : 430 9.
17. Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int. J. Cancer 2004 108 : 643 53.
18. Zeineldin R, Rosenberg M, Ortega D, Buhr C, Chavez MG et al. Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Mol. Carcinog. 2006 45 : 851 60.
19. Damstrup L, Wandahl PM, Bastholm L, Elling F, Skovgaard PH et al. Epidermal growth factor receptor mutation type III transfected into a small cell lung cancer cell line is predominantly localized at the cell surface and enhances the malignant phenotype. Int. J. Cancer 2002 97 : 7 14.
20. Frame MC. Src in cancer: deregulation and consequences for cell behaviour. Biochim. Biophys. Acta. 2002 1602 : 114 30.
21. Janda E, Lehmann K, Killisch I, Jechlinger M, Herzig M et al. Ras and TGF [beta] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J. Cell. Biol. 2002 156 : 299 313.
22. Edme N, Downward J, Thiery JP, Boyer B. Ras induces NBT-II epithelial cell scattering through the coordinate activities of Rac and MAPK pathways. J. Cell Sci. 2002 115 : 2591 601.
23. Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003 63 : 2172 8.
24. Tsao MS, Sakurada A, Cutz JC, Zhu CQ, Kamel-Reid S et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N. Engl. J. Med. 2005 353 : 133 44.
25. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 2005 97 : 339 46.
26. Huang SF, Liu HP, Li LH, Ku YC, Fu YN et al. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 2004 10 : 8195 203.